Login to Your Account



BIO CEO & Investor Conference

Dissecting impacts of U.S. tax code changes: The good, the bad and the uncertain

By Jennifer Boggs
Managing Editor

Wednesday, February 14, 2018

NEW YORK – The double-digit reduction in the corporate tax rate and the repatriation provision included in the tax code changes signed into law late last year were hailed as boons for the U.S. biopharma sector, with many pundits predicting that 2018 will finally bring a much-anticipated M&A frenzy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription